Transthyretin Amyloid Cardiomyopathy Clinical Trial

Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy

Summary

This study will examine the clinical effectiveness of Tafamidis in patients with Mixed Phenotype Transthyretin Amyloidosis using data that already exist in patients' medical records

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Age ≥18 years at diagnosis.
Diagnosed with ATTRv-CM or ATTRwt-CM, mixed phenotype.
Treated with tafamidis, as VYNDAMAX 61 mg [one 61-mg tafamidis capsule] orally once daily for ≥12 months.
Have had ≥1 pre- and ≥1 post-treatment neurologic assessments.

Exclusion Criteria:

History of any organ transplant.
Individuals who are non-ambulatory.
Prior or current treatment with any disease-modifying therapy (investigational or approved) alone or in combination, except tafamidis, as VYNDAQEL 80 mg [four 20-mg tafamidis meglumine capsules] orally once daily or VYNDAMAX 61 mg [one 61-mg tafamidis capsule] orally once daily.
Peripheral neuropathy attributed to causes other than ATTR amyloidosis (eg, diabetes mellitus, B12 deficiency, hypothyroidism, shingles,Lyme disease, HIV infection, secondary to injury, chronic kidney disease).
Patient's data fails to pass data quality checks.

Study is for people with:

Transthyretin Amyloid Cardiomyopathy

Estimated Enrollment:

50

Study ID:

NCT06393465

Recruitment Status:

Not yet recruiting

Sponsor:

Pfizer

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Pfizer
New York New York, 10001, United States

How clear is this clinincal trial information?

Study is for people with:

Transthyretin Amyloid Cardiomyopathy

Estimated Enrollment:

50

Study ID:

NCT06393465

Recruitment Status:

Not yet recruiting

Sponsor:


Pfizer

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.